US Bancorp
CLYM icon

US Bancorp’s Climb Bio CLYM Stock Holding History

US Bancorp’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.7K Buy
+3,120
New +$32.2K ﹤0.01% 2899
2024
Q4 		– Sell
-141
Closed -$718 – 4284
2024
Q3 		$718 Buy
+141
New +$997 ﹤0.01% 3924

Other funds holding CLYM

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

US Bancorp's CLYM Position: Q2 2026 in Review

US Bancorp opened a new position in Climb Bio (CLYM) in Q2 2026: 3,120 shares worth $40.7K. The stake represents ﹤0.01% of the portfolio and ranks #2899 among its holdings. This is a return to the name: US Bancorp previously reported a position in CLYM as recently as Q3 2024.

US Bancorp first reported a position in CLYM in Q3 2024 and has held it in 2 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • US Bancorp held 3,120 shares of Climb Bio worth $40.7K as of Q2 2026.
  • Climb Bio was a new US Bancorp position in Q2 2026.
  • Climb Bio made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2899 holding.
  • US Bancorp first reported a position in Climb Bio in Q3 2024 and has held it in 2 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.